| abstract |
[Chemical 1] The present invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, their synthesis, selection and use of such conjugates for cancer therapy or other diseases mediated by cell proliferation, cell migration or inflammation. Regarding use, and the pathology includes angiogenesis or neovascularization of new tissue. The invention further relates to a combination treatment of such diseases, wherein the treatment comprises the use of a conjugate in combination with one or more other therapeutic modalities including but not limited to chemotherapy, surgery or radiation therapy. . Preferred conjugates include maytansinoid compounds linked to antibodies by disulfide bonds, and preferably the chemotherapeutic agent is deoxorubicin, taxane, camptothecin, podophyllotoxin, nucleoside analogue or pyrimidine analogue. |